About US
Contact us
-
Novartis receives clinical recommendation in Australia for meningitis B vaccineNovartis has received clinical recommendation from the Australian Technical Advisory Group on Immunisation (ATAGI) for its Bexsero meningococcal group B vaccine (rDNA, component, adsorbed) for use in2014/3/18
-
FDA approves Mallinckrodt's pain drug XARTEMIS XRThe US Food and Drug Administration (FDA) has approved Irish pharmaceutical firm Mallinckrodt's XARTEMIS XR extended-release tablets (CII), previously known as MNK-795, for treatment of acute pain. X2014/3/18
-
Teva enters into partnership with UK Government on dementia researchIsraeli firm Teva has entered into a $21m agreement with the UK Government's National Health Service National Institute for Health Research (NIHR) Office for Clinical Research Infrastructure (NOCRI) f2014/3/17
-
TC BioPharm collaborates with Medinet for new cancer immuno-cell therapyScotland-based biotechnology firm TC BioPharm (TCB) has entered into a strategic collaboration with Medinet, a Japanese immuno-cell therapy company, for developing a new treatment for different types2014/3/17
-
Upsher-Smith's antiepileptic drug Qudexy XR gets FDA approvalUpsher-Smith Laboratories (Upsher-Smith) has secured approval from the US Food and Drug Administration (FDA) for Qudexy XR (topiramate) extended-release capsules, indicated as initial monotherapy in p2014/3/14
-
AstraZeneca introduces combination drug Xigduo in UK for type 2 diabetesAstraZeneca has launched its twice-daily tablet Xigduo (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1000mg tablets) in the UK to treat patients with type 2 diabetes. Xigduo is the2014/3/14
-
Activate your visitor badge today6-8 May 2014Palexpo, Geneva, Switzerland ACTIVATE YOUR VISITOR BADGE FOR VITAFOODS EUROPE 20142014/3/13
-
Remarkable Keynote Speakers - ExcipientFest Americas 2014Check our Educational Summary View this email in your browser. APRIL 28-30, 2014 Raleigh Convention CenterRaleigh - NCwww.excipientfest.com2014/3/13
-
Bayer announces approval of Adempas for hypertension treatmentBayer Canada has announced that Adempas (riociguat tablets) has now been approved for treating patients with pulmonary arterial hypertension (PAH). Bayer claims that Adempas, a soluble guanylate cycl2014/3/12
-
Novartis' Urticaria drug Xolair obtains EU approvalNovartis has received approval from the European Commission (EC) to use Xolair (omalizumab) as an add-on therapy to treat chronic spontaneous urticaria (CSU) in adult and adolescent patients 12 years2014/3/12